Abstract #0512

DSC-MRI Measures of Standardized RCBV Predict Response to Bevacizumab in High-Grade Brain Tumor Patients

Kathleen M. Schmainda¹, Melissa A. Prah¹, Scott D. Rand¹, Jennifer Connelly², Eric S. Paulson³, Peter S. LaViolette¹, Wade Mueller⁴, Mark G. Malkin²

¹Radiology, Medical College of Wisconsin, Milwaukee, WI, United States; ²Neurology, Medical College of Wisconsin, Milwaukee, WI, United States; ³Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States; ⁴Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, United States

Standard measures of tumor volume derived from contrast-enhancing T1-weighted images, or abnormal volumes on T2-weighted images do not reliably predict the response of brain tumors to anti-angiogenic therapies such as bevacizumab. Bevacizumab may result in decreases in enhancing tumor volume without an effect on the tumor biology. In this study we show that standardized relative cerebral blood volume (rCBV) information, derived from DSC MRI, can predict the overall survival (OS) of high-grade gliomas to bevacizumab therapy. If the rCBV is low either before or after treatment, the OS is significantly improved.